Target intelligence / Profile preview

CUGBP Elav-like family member 1 (CELF1)

Target
CELF1
Molecular classification
RNA-binding protein, Post-transcriptional regulator, Splicing factor, Member of ELAV-like RBP family
01

Overview

CELF1 is a pivotal post-transcriptional regulator with three RNA recognition motifs that bind GU-rich elements within target mRNAs. It orchestrates alternative splicing, translation, and mRNA decay, thus modulating key processes such as cell proliferation, apoptosis, differentiation, and migration. CELF1’s dysregulation contributes to multiple pathologies—including myotonic dystrophy and diverse cancers (where it promotes tumor growth, EMT, and metastasis). As a central node in post-transcriptional gene regulation, CELF1 is considered a promising but complex therapeutic target. There are significant challenges to its clinical modulation, given its broad essential functions for normal cellular homeostasis.

Other names
CUG-binding protein 1CUGBP1BRUNOL2NAB50EDEN-BP homologRNA-binding protein BRUNOL-2Bruno-like protein 2CUG triplet repeat RNA-binding protein 1CUG-BP- and ETR-3-like factor 1Deadenylation factor CUG-BPhNab50NAPOR50 kDa nuclear polyadenylated RNA-binding proteinEmbryo deadenylation element-binding protein homolog
02

Mechanism of action

Proposed for research molecules: modulation of RNA-binding activity to alter splicing, translation, or stability of disease-associated mRNAs

03

Biological functions

Regulation of alternative splicingRegulation of mRNA stability and decayControl of mRNA translation initiation and repressionCell cycle regulationRegulation of cell proliferationApoptosis modulationEpithelial-mesenchymal transition (EMT) and metastasis
04

Disease associations

Myotonic dystrophy type 1 (DM1)Cancer (notably breast, lung, head & neck squamous cell carcinoma)Neurodegenerative disease (e.g., fragile-X tremor/ataxia syndrome)Liver dysfunction
05

Safety considerations

Targeting CELF1 carries potential risks of off-target effects due to its widespread physiological RNA regulatory functions (e.g., cell cycle, apoptosis, tissue development). Knockout models exhibit embryonic lethality.Challenge in specifically modulating CELF1 activity without disturbing normal post-transcriptional regulation in vital tissues.
06

Interacting drugs

No approved drugs directly targeting CELF1 are currently described in the literature. Research is ongoing into RNA therapeutics and small molecules indirectly affecting CELF1-related pathways.
07

Biomarkers

CELF1 protein overexpression in tumor tissue (prognostic marker in head & neck, breast, and lung cancers)CELF1 levels in DM1 muscle tissuemRNAs regulated by CELF1 (e.g., MYC, IL24, MMP1)

Beyond the preview

Go deeper on CUGBP Elav-like family member 1 (CELF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUGBP Elav-like family member 1 (CELF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call